theory clinical_95_8
imports Main

begin

typedecl entity
typedecl event

consts
  Patients :: "entity ⇒ bool"
  V600EMutation :: "entity ⇒ bool"
  Treatment :: "entity ⇒ bool"
  Vemurafenib :: "entity ⇒ bool"
  Receive :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  With :: "entity ⇒ entity ⇒ bool"
  Recovery :: "entity ⇒ bool"
  MAPKPathwaySignaling :: "entity ⇒ bool"
  Resistance :: "entity ⇒ bool"
  BRAFInhibitors :: "entity ⇒ bool"
  AssociatedWith :: "entity ⇒ entity ⇒ bool"
  MEKInhibitors :: "entity ⇒ bool"
  Help :: "event ⇒ bool"
  Prevent :: "event ⇒ bool"
  Overcome :: "event ⇒ bool"
  CombinationTherapies :: "entity ⇒ bool"
  MEKInhibitor :: "entity ⇒ bool"
  Monotherapy :: "entity ⇒ bool"
  Effective :: "event ⇒ bool"
  Than :: "entity ⇒ entity ⇒ bool"
  Effectiveness :: "event ⇒ bool"
  Leads :: "event ⇒ bool"
  BetterResults :: "entity ⇒ bool"
  ClinicalOutcomes :: "entity ⇒ bool"
  Yield :: "event ⇒ bool"
  From :: "entity ⇒ entity ⇒ bool"
  Combination :: "entity ⇒ bool"

(* Explanation 1: Patients with V600E mutation could receive treatment with vemurafenib. *)
axiomatization where
  explanation_1: "∃x y z e. Patients x ∧ V600EMutation x ∧ Treatment y ∧ Vemurafenib z ∧ Receive e ∧ Agent e x ∧ Patient e y ∧ With y z"

(* Explanation 2: Rapid recovery of MAPK pathway signaling is associated with resistance to BRAF inhibitors. *)
axiomatization where
  explanation_2: "∃x y. Recovery x ∧ MAPKPathwaySignaling x ∧ Resistance y ∧ BRAFInhibitors y ∧ AssociatedWith x y"

(* Explanation 3: MEK inhibitors can help prevent the rapid recovery of MAPK pathway signaling, potentially overcoming resistance to BRAF inhibitors. *)
axiomatization where
  explanation_3: "∃x y z e1 e2 e3. MEKInhibitors x ∧ Recovery y ∧ MAPKPathwaySignaling y ∧ Resistance z ∧ BRAFInhibitors z ∧ Help e1 ∧ Agent e1 x ∧ Prevent e2 ∧ Patient e2 y ∧ Overcome e3 ∧ Agent e3 z"

(* Explanation 4: Combination therapies, such as vemurafenib with a MEK inhibitor, are often more effective in overcoming resistance than vemurafenib monotherapy, and this effectiveness directly leads to better results than monotherapy. *)
axiomatization where
  explanation_4: "∃x y z w e1 e2 e3. CombinationTherapies x ∧ Vemurafenib y ∧ MEKInhibitor y ∧ Resistance z ∧ Monotherapy w ∧ Effective e1 ∧ Agent e1 x ∧ Overcome e3 ∧ Agent e3 z ∧ Than y w ∧ Effectiveness e2 ∧ Leads e2 ∧ Agent e2 x ∧ BetterResults y ∧ Than y w"

(* Explanation 5: Better clinical outcomes from combination therapies often yield better results than monotherapy. *)
axiomatization where
  explanation_5: "∃x y z e. ClinicalOutcomes x ∧ CombinationTherapies y ∧ BetterResults z ∧ Monotherapy w ∧ Yield e ∧ Agent e x ∧ Patient e z ∧ From x y ∧ Than z w"

theorem hypothesis:
  assumes asm: "Combination x ∧ Vemurafenib y ∧ MEKInhibitor y"
  (* Hypothesis: Combination of vemurafenib and a MEK inhibitor may yield better results than vemurafenib monotherapy. *)
  shows "∃x y e. Combination x ∧ Vemurafenib y ∧ MEKInhibitor y ∧ Yield e ∧ Agent e x ∧ Patient e y ∧ BetterResults y ∧ Monotherapy z ∧ Than y z"
proof -
  (* From the premise, we have known information about the combination, vemurafenib, and MEK inhibitor. *)
  from asm have "Combination x ∧ Vemurafenib y ∧ MEKInhibitor y" by blast
  (* There is a logical relation Implies(F, G), Implies(Combination therapies are used, Better clinical outcomes are achieved) *)
  (* F is from explanatory sentence 4, G is from explanatory sentence 5. *)
  (* We already have Combination x, so we can infer Better clinical outcomes are achieved. *)
  then have "BetterResults y" sledgehammer
  (* Explanation 5 states that better clinical outcomes from combination therapies often yield better results than monotherapy. *)
  (* We can use this to infer the hypothesis. *)
  then have "Yield e ∧ Agent e x ∧ Patient e y ∧ Monotherapy z ∧ Than y z" <ATP>
  then show ?thesis <ATP>
qed

end
